Previous 10 | Next 10 |
2023-08-07 14:40:25 ET Compugen Ltd. (CGEN) Q2 2023 Earnings Conference Call August 7, 2023 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto ...
2023-08-07 07:02:20 ET Compugen press release ( NASDAQ: CGEN ): Q2 GAAP EPS of -$0.11 beats by $0.02 . As of June 30, 2023, cash, cash equivalents and cash investments were approximately $66.5 million, compared with approximately $83.7 million as of December 31, 2022. ...
Compugen Reports Second Quarter 2023 Results PR Newswire Advancing enrollment in two proof-of-concept studies evaluating triple blockade of DNAM-1 axis in patients with microsatellite stable colorectal cancer and platinum resistant ovarian cancer; initial findings expecte...
2023-08-04 13:19:15 ET Compugen ( NASDAQ: CGEN ) is scheduled to announce Q2 earnings results on Monday, August 7th, before market open. The consensus EPS Estimate is -$0.12 For further details see: Compugen Q2 Earnings Preview
Compugen to Release Second Quarter 2023 Results on Monday, August 7, 2023 PR Newswire HOLON, Israel , July 24, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target d...
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party PR Newswire Patent EP3258951B1 , Anti-PVRIG Antibodies and Methods of Use, granted by the European Patent Office covers any anti-PVRIG antibody which activates T cells and/or NK cells f...
Compugen Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-of-Concept Study PR Newswire Study builds on clinical benefit reported in heavily pretreated platinum resistant ovarian cancer patients tre...
2023-06-13 08:11:33 ET Compugen ( NASDAQ: CGEN ) said on Tuesday that it has received a Nasdaq notice on having regained compliance with the stock exchange's minimum bid price requirement. The company was notified on November 2, 2022 by Nasdaq, of it...
Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire HOLON, Israel , June 13, 2023 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target disco...
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer PR Newswire COM701 in combination with nivolumab and BMS-986207 (anti-TIGIT) resulted in encoura...
News, Short Squeeze, Breakout and More Instantly...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...